Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial by Israel Elliot, Chinchilli Vernon M, Ford Jean G, Boushey Homer A, Cherniack Reuben, Craig Timothy J, Deykin Aaron, Fagan Joanne K, Fahy John V, Fish James, Kraft Monica, Kunselman Susan J, Lazarus Stephen C, Lemanske Robert F, Liggett Stephen B, Martin Richard J, Mitra Nandita, Peters Stephen P, Silverman Eric, Sorkness Christine A, Szefler Stanley J, Wechsler Michael E, Weiss Scott T, Drazen Jeffrey M, National Heart, Lung, and Blood Institute's Asthma Clinical Research Network in Lancet (2004).

[PMID: 15500895] PubMed


The issue of whether regular use of an inhaled beta2-adrenergic agonist worsens airflow and clinical outcomes in asthma is controversial. Retrospective studies have suggested that adverse effects occur in patients with a genetic polymorphism that results in homozygosity for arginine (Arg/Arg), rather than glycine (Gly/Gly), at aminoacid residue 16 of the beta2-adrenergic receptor. However, the existence of any genotype-dependent difference has not been tested in a prospective clinical trial.

[ hide abstract ]

Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Rx Annotations

No dosing information annotated.